+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 33 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.

Age: 18Years +All GendersPhase 2
331 locations
P

Actively Recruiting

Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.

All AgesAll GendersPhase 3
629 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
S

Actively Recruiting

Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.

Age: 18Years +All GendersPhase 2Phase 3
378 locations
R

Actively Recruiting

Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.

Age: 18Years +All GendersPhase 2
456 locations
B

Actively Recruiting

Researchers are evaluating the effects of combining two drugs, cabozantinib and nivolumab, in treating patients with advanced melanoma or squamous cell head and neck cancer that may have spread to nearby tissues, lymph nodes, or distant parts of the body. This phase II study aims to assess how quickly patients can be grouped based on tumor biomarkers called tumor mutational burden and tumor inflammation signature, and to learn if the combination can shrink or stabilize the cancer depending on these biomarker statuses. Participants receive nivolumab through an intravenous infusion on the first day of each 28-day treatment cycle and take cabozantinib orally daily. Treatment cycles continue for up to two years unless the cancer progresses or unacceptable side effects occur. Throughout the trial, patients undergo CT or MRI scans and blood sample collections. Tumor biopsies are taken during screening and optionally during follow-up. After completing treatment, participants are followed up every 12 weeks for one year and then every six months up to three years after registration. During the study, patients will be monitored with imaging scans and laboratory tests to assess tumor response and safety. Researchers will measure how quickly biomarker results are available and evaluate overall response rates, disease control, progression-free survival, and overall survival over two years. Safety and tolerability of the drug combination will also be assessed, along with the identification of biomarkers that might predict treatment response or side effects. Specimens will be collected and stored for future research.

Age: 18Years +All GendersPhase 2
232 locations
C

Actively Recruiting

Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.

Age: 70Years +All GendersPhase 3
329 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
R

Actively Recruiting

Researchers are comparing two treatments, rituximab and mosunetuzumab, for patients with follicular lymphoma that has a low tumor burden. This phase III trial aims to see which treatment better helps patients avoid disease progression or worsening over time. Both drugs are monoclonal antibodies targeting cancer cells, but it is unknown which one is more effective for this condition. Participants are randomly assigned to one of two groups. One group receives rituximab intravenously on day 1 of the first cycle, then rituximab with hyaluronidase subcutaneously on days 8, 15, and 22 of the first cycle and on day 1 of later cycles cycles repeat every 56 days for up to 5 cycles. The other group receives mosunetuzumab subcutaneously on days 1, 8, and 15 of the first cycle and day 1 of later cycles cycles repeat every 21 days for up to 8 cycles. During treatment, participants have CT or PETCT scans and blood samples collected. After treatment, participants are followed every 6 months for 5 years and then yearly up to 10 years. Researchers assess progression-free survival, overall survival, response rates, event-free survival, and treatment side effects. Specimens are also collected for future research. The total participation may last up to 10 years, including long-term monitoring for disease status and safety.

Age: 18Years +All GendersPhase 3
288 locations

1-10 of 33

1